Home › Funds › Opaleye Management Inc. › BBOT

Opaleye Management Inc. position in BBOT

BridgeBio Oncology Therapeutic Inc · Health Care

Opaleye Management Inc. reported holding 700,000 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$5.3M, representing 0.48% of its reported portfolio and ranking #34 among its reported holdings. Opaleye Management Inc. has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)700.00K sh
Reported value held$5.33M
Portfolio Weight0.48%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Opaleye Management Inc.'s BBOT position evolved

Opaleye Management Inc. first disclosed a stake in BBOT in Q1 2026 at 53,282 shares (US$477K). The position peaked in Q2 2026 at 700,000 shares, worth US$5.3M. Across 2 filings, Opaleye Management Inc. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 700,000 shares valued at US$5.3M — an increase of 646,718 shares quarter over quarter.. Notable position changes include a 1214% increase in Q2 2026 (shares fell 46% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 53.28K $476.87K New
Q2 2026 700.00K $5.33M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBOT and 13F data

BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBOT

All BBOT fund holders →

FAQ

How long has Opaleye Management Inc. held BBOT?

Opaleye Management Inc. has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Opaleye Management Inc.'s current position in BBOT?

As of Q2 2026, Opaleye Management Inc. holds 700.00K shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $5.33M, representing 0.48% of its reported portfolio and ranking #34.

Has Opaleye Management Inc. been buying or selling BBOT?

In the latest 13F filing (Q2 2026), Opaleye Management Inc. increased its position in BBOT. The position peaked in Q2 2026 at 700.00K shares.

Which other funds hold BBOT?

Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.